Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant equine interleukin-31
- Development stage
- Preclinical
- Lead developer
- unspecific (research groups; main research from University of Edinburgh and University of Zurich/Swiss collaborations)
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intradermal (id; In Experiments)
01
Overview
recombinant equine interleukin-31 is a recombinant form of interleukin-31 (IL-31) derived from horses. It is a cytokine protein involved in mediating immune responses, particularly pruritus (itch) associated with allergic conditions such as insect bite hypersensitivity (IBH) and atopic dermatitis in horses. Recombinant eIL-31 has been produced using both mammalian and bacterial expression systems for use in research and as a model for pruritic disorders in horses. Its biological mechanism involves activation of the IL-31 receptor, leading to pruritus via pathways such as STAT3 phosphorylation in immune cells. It is also being studied as a target antigen for active vaccination strategies aiming to reduce clinical allergic itch in horses[1][2][3][4][5].
- Other names
- eIL-31eIL31eIL 31equine IL-31recombinant eIL-31
02
Targets
IL31RA (IL-31 receptor alpha)
Beyond the preview
Go deeper on recombinant equine interleukin-31.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant equine interleukin-31.